The same group also aims to evaluate the safety and efficacy of 177Lu-PSMA radioligand therapy in patients with recurrent or metastatic ACC and SDC with PSMA ligand uptake (NCT04291300). Here, FOLH1 is linked to adrenal cortex carcinoma.